Heron Therapeutics Q2 2024 GAAP EPS $(0.06) Misses $(0.04) Estimate, Sales $36.024M Beat $35.888M Estimate
Author: Benzinga Newsdesk | August 06, 2024 04:17pm
Heron Therapeutics (NASDAQ:
HRTX) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.04) by 50 percent. The company reported quarterly sales of $36.024 million which beat the analyst consensus estimate of $35.888 million by 0.38 percent. This is a 13.42 percent increase over sales of $31.762 million the same period last year.
Posted In: HRTX